| NCT07017725 | A Dose-escalation Study Followed by a Dose Optimal Study to Evaluate the Safety and Efficacy of CID-103 in Adults With Chronic Immune Thrombocytopenia | RECRUITING | PHASE1, PHASE2 | 2025-01-03 | 2026-12-30 | 2026-06-01 |
| NCT04758767 | CID-103 (Anti-CD38 Antibody) in Previously Treated Relapsed or Refractory Multiple Myeloma | COMPLETED | PHASE1 | 2021-03-22 | 2023-01-19 | 2023-01-19 |
| NCT02234986 | A Multi-center, Open-label Study of Oral ENMD-2076 for the Treatment of Patients With Advanced Fibrolamellar Carcinoma | COMPLETED | PHASE2 | 2015-10 | 2018-06-30 | 2018-06-30 |
| NCT01639248 | Phase 2 Study - Aurora + Angiogenic Kinase Inhibitor ENMD-2076 in Previously Treated Locally Advanced + Metastatic TNBC | COMPLETED | PHASE2 | 2012-07 | 2017-06 | 2017-06 |
| NCT01104675 | Study of Oral ENMD-2076 Administered to Patients With Ovarian Cancer | COMPLETED | PHASE2 | 2010-04 | 2012-12 | 2011-08 |
| NCT00904787 | Study of ENMD-2076 in Patients With Relapsed or Refractory Hematological Malignancies | COMPLETED | PHASE1 | 2009-04 | 2011-05 | 2010-12 |
| NCT00806065 | Study of ENMD-2076 in Patients With Multiple Myeloma | COMPLETED | PHASE1 | 2008-12 | 2012-01 | 2011-11 |
| NCT00658671 | A Dose-Escalation Study of ENMD-2076 Administered Orally to Patients With Advanced Cancer | COMPLETED | PHASE1 | 2008-04 | 2012-06 | 2010-12 |
| NCT00656461 | Phase 1 Study of MKC-1 in Patients With Advanced Cancer | COMPLETED | PHASE1 | 2008-03 | 2009-11 | 2009-07 |
| NCT00607607 | A Phase 2 Study of Oral MKC-1 in Patients With Ovarian or Endometrial Cancer | COMPLETED | PHASE2 | 2008-01 | 2012-01 | 2011-06 |
| NCT00568646 | Phase 2 Study of Oral MKC-1 in Patients With Unresectable or Metastatic Pancreatic Cancer | COMPLETED | PHASE2 | 2007-11 | 2009-05 | 2009-04 |
| NCT00481455 | Phase 2 Study of Panzem Nanocrystal Colloidal Dispersion (NCD) in Combination With Fixed-Dose Temozolomide to Patients With Recurrent Glioblastoma Multiforme (GBM) | COMPLETED | PHASE2 | 2007-04 | 2008-10 | 2007-09 |
| NCT00444314 | Phase 2 Study of Panzem® NCD Alone and Combined With Sunitinib Malate in Patients With Metastatic Renal Cell Carcinoma | COMPLETED | PHASE2 | 2007-02 | 2009-10 | 2008-12 |
| NCT00506402 | A Phase 1 Study of MKC-1 in Patients With Refractory Hematologic Malignancies | COMPLETED | PHASE1 | 2006-11 | 2009-04 | 2009-01 |
| NCT00394810 | Efficacy and Pharmacodynamic Study of Panzem® NCD in Patients With Hormone-Refractory Prostate Cancer | COMPLETED | PHASE2 | 2006-11 | 2008-11 | 2008-11 |
| NCT00408226 | Safety Study of MKC-1 Combined With Pemetrexed to Treat Advanced Cancer and Non-Small Cell Lung Cancer | COMPLETED | PHASE1, PHASE2 | 2006-10 | 2012-01 | 2009-06 |
| NCT00400348 | Safety and Efficacy Study of Panzem® Nanocrystal Colloidal Dispersion in Patients With Ovarian Cancer | COMPLETED | PHASE2 | 2006-10 | 2008-11 | 2008-08 |
| NCT00328497 | A Combination Study to Determine the Safety and Efficacy of Panzem NCD With Avastin in Metastatic Carcinoid Tumors | COMPLETED | PHASE2 | 2006-05 | 2009-12 | 2008-12 |
| NCT00306631 | A Study to Determine the Antitumor Activity and Evaluate the Safety of MKC-1 | COMPLETED | PHASE2 | 2006-01 | 2008-11 | 2008-04 |
| NCT00306618 | Safety and Efficacy Study of Panzem NCD to Treat Glioblastoma | COMPLETED | PHASE2 | 2006-01 | 2008-12 | 2007-11 |
| NCT00592579 | A Phase 2 Study With Panzem in Patients With Relapsed or Plateau Phase Multiple Myeloma | COMPLETED | PHASE2 | 2001-03 | 2008-09 | 2008-09 |
| NCT00049790 | Safety and Efficacy Study of rhAngiostatin Administered in Combination With Paclitaxel and Carboplatin to Patients With Non-Small-Cell Lung Cancer | COMPLETED | PHASE2 | | 2004-12 | |